Infections present before transplant
| . | Patients infected at any time before HCT, n (%) . | Patients with active infection at time of transplant, n (%) . | ||
|---|---|---|---|---|
| ≥1 Infection in all subjects (N = 98)* | 61 (62) | 37 (38) | ||
| ≥1 Infection in subgroups | ||||
| Diagnosed by NBS/FH (N = 59) | 25 (42) | 16 (27) | ||
| Diagnosed by clinical signs (N = 39) | 36 (92) | 21 (54) | ||
| <3.5 mo at time of HCT (N = 42) | 16 (38) | 7 (17) | ||
| >3.5 mo at time of HCT (N = 56) | 45 (80) | 30 (54) | ||
| Organism category | Clinical signs subgroup (N = 39), n (%) | NBS/FH subgroup (N = 59), n (%) | Clinical signs subgroup (N = 39), n (%) | NBS/FH subgroup (N = 59), n (%) |
| Staphylococcal infections | 6 (15) | 7 (12) | 1 (3) | 1 (2) |
| Gram-negative bacterial infections (Klebsiella, Pseudomonas, Escherichia, Enterobacter, Acinetobacter, Aeromonas, Branhamella/Moraxcella, Elizabethkingia, Haemophilus, Legionella, Neisseria, Salmonella, Stenotrophomonas) | 16 (41) | 4 (7) | 1 (3) | 0 |
| Clostridium difficile infection | 3 (8) | 4 (7) | 2 (5) | 3 (5) |
| Other bacterial infection | 14 (36) | 1 (2) | 1 (3) | 0 |
| Mycobacterial infection | 2 (5) | 0 | 1 (3) | 0 |
| Candida species infections | 6 (15) | 5 (8) | 0 | 0 |
| PJP Infections | 11 (28) | 0 | 1 (3) | 0 |
| Respiratory viral infections (rhinovirus, RSV, parainfluenza, influenza) | 22 (56) | 9 (15) | 10 (26) | 5 (8) |
| Double-stranded DNA viral infections (CMV, varicella, EBV, herpes simplex virus, adenovirus | 11 (28) | 10 (17) | 7 (18) | 7 (12) |
| Rotavirus infection | 1 (3) | 1 (2) | 1 (3) | 0 |
| Hepatitis B | 1 (3) | 0 | 0 | 0 |
| Parvovirus | 1 (3) | 0 | 0 | 0 |
| No organism identified, clinical signs present | 4 (10) | 0 | 0 | 0 |
| . | Patients infected at any time before HCT, n (%) . | Patients with active infection at time of transplant, n (%) . | ||
|---|---|---|---|---|
| ≥1 Infection in all subjects (N = 98)* | 61 (62) | 37 (38) | ||
| ≥1 Infection in subgroups | ||||
| Diagnosed by NBS/FH (N = 59) | 25 (42) | 16 (27) | ||
| Diagnosed by clinical signs (N = 39) | 36 (92) | 21 (54) | ||
| <3.5 mo at time of HCT (N = 42) | 16 (38) | 7 (17) | ||
| >3.5 mo at time of HCT (N = 56) | 45 (80) | 30 (54) | ||
| Organism category | Clinical signs subgroup (N = 39), n (%) | NBS/FH subgroup (N = 59), n (%) | Clinical signs subgroup (N = 39), n (%) | NBS/FH subgroup (N = 59), n (%) |
| Staphylococcal infections | 6 (15) | 7 (12) | 1 (3) | 1 (2) |
| Gram-negative bacterial infections (Klebsiella, Pseudomonas, Escherichia, Enterobacter, Acinetobacter, Aeromonas, Branhamella/Moraxcella, Elizabethkingia, Haemophilus, Legionella, Neisseria, Salmonella, Stenotrophomonas) | 16 (41) | 4 (7) | 1 (3) | 0 |
| Clostridium difficile infection | 3 (8) | 4 (7) | 2 (5) | 3 (5) |
| Other bacterial infection | 14 (36) | 1 (2) | 1 (3) | 0 |
| Mycobacterial infection | 2 (5) | 0 | 1 (3) | 0 |
| Candida species infections | 6 (15) | 5 (8) | 0 | 0 |
| PJP Infections | 11 (28) | 0 | 1 (3) | 0 |
| Respiratory viral infections (rhinovirus, RSV, parainfluenza, influenza) | 22 (56) | 9 (15) | 10 (26) | 5 (8) |
| Double-stranded DNA viral infections (CMV, varicella, EBV, herpes simplex virus, adenovirus | 11 (28) | 10 (17) | 7 (18) | 7 (12) |
| Rotavirus infection | 1 (3) | 1 (2) | 1 (3) | 0 |
| Hepatitis B | 1 (3) | 0 | 0 | 0 |
| Parvovirus | 1 (3) | 0 | 0 | 0 |
| No organism identified, clinical signs present | 4 (10) | 0 | 0 | 0 |
Patients with RD excluded.